Profile data is unavailable for this security.
About the company
Revvity, Inc. is a provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. The Company has specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards the life sciences market. The segment offers instruments, reagents, software, detection and imaging technologies, and others. The Diagnostics segment develops diagnostics, tools, and applications focused on clinically oriented customers, within the reproductive health, immunodiagnostics, and applied genomics markets. The segment offers instruments, reagents, assay platforms and software to hospitals, medical labs, clinicians and medical research professionals to help improve the health of families.
- Revenue in USD (TTM)2.86bn
- Net income in USD239.88m
- Incorporated1947
- Employees11.00k
- LocationRevvity Inc77 4Th AvenueWALTHAM 02451United StatesUSA
- Phone+1 (781) 663-6900
- Websitehttps://www.revvity.com/
More ▼
Mergers & acquisitions
| Acquired company | RVTY:NYQ since announced | Transaction value |
|---|---|---|
| Advanced Chemistry Development Inc | 5.56% | 80.00m |
| Spring Discovery Inc | -14.55% | -- |
Data delayed at least 15 minutes, as of Mar 03 2026 19:18 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bruker Corp | 3.44bn | -22.50m | 6.06bn | 11.09k | -- | 2.47 | 30.44 | 1.76 | -0.1485 | -0.1485 | 22.63 | 16.15 | 0.5705 | 1.64 | 5.22 | 310,013.50 | -0.1212 | 5.07 | -0.1553 | 6.76 | 47.13 | 49.70 | -0.2124 | 7.56 | 0.8553 | 9.30 | 0.4268 | 13.19 | 2.08 | 11.57 | -119.89 | -- | 4.34 | 4.56 |
| Glaukos Corp | 507.44m | -187.69m | 7.03bn | 1.09k | -- | 10.62 | -- | 13.86 | -3.27 | -3.27 | 8.87 | 11.41 | 0.5432 | 1.84 | 5.99 | 463,840.90 | -20.09 | -12.56 | -22.19 | -13.55 | 77.97 | 76.60 | -36.99 | -34.64 | 4.06 | -- | 0.094 | -- | 32.33 | 17.67 | -28.23 | -- | 28.47 | -- |
| Repligen Corp | 738.26m | 48.89m | 7.04bn | 2.00k | 144.59 | 3.34 | 55.15 | 9.54 | 0.8643 | 0.8643 | 13.05 | 37.39 | 0.2555 | 2.23 | 5.04 | 369,128.00 | 1.69 | 2.88 | 1.77 | 3.20 | 52.65 | 53.58 | 6.62 | 10.73 | 7.12 | -- | 0.2047 | 0.00 | 16.36 | 15.05 | 291.64 | -3.99 | -0.4706 | -- |
| Bio Rad Laboratories Inc | 2.58bn | 759.90m | 7.49bn | 7.45k | 10.02 | 1.01 | 8.10 | 2.90 | 27.91 | 27.91 | 94.69 | 276.16 | 0.2591 | 1.65 | 5.66 | 346,738.30 | 7.62 | -1.69 | 8.02 | -1.77 | 52.01 | 54.52 | 29.42 | -8.08 | 4.19 | -- | 0.139 | -- | 0.6507 | 0.2935 | 141.20 | -27.58 | 7.74 | -- |
| Masimo Corp | 1.53bn | 207.70m | 9.16bn | 2.20k | 45.25 | 12.67 | 37.16 | 6.00 | 3.88 | -2.77 | 28.42 | 13.84 | 0.7062 | 1.39 | 4.42 | 694,045.40 | 9.61 | 5.65 | 12.45 | 6.99 | 61.90 | 58.51 | 13.60 | 9.43 | 1.47 | 8.39 | 0.421 | 0.00 | 9.44 | 5.95 | 1,182.10 | -2.87 | -20.94 | -- |
| Henry Schein Inc | 13.18bn | 398.00m | 9.33bn | 25.00k | 24.88 | 2.90 | 13.00 | 0.7079 | 3.27 | 3.27 | 108.32 | 28.03 | 1.23 | 4.76 | 8.42 | 527,360.00 | 3.80 | 5.06 | 6.56 | 8.59 | 31.14 | 30.81 | 3.09 | 3.79 | 0.7627 | 6.54 | 0.3932 | 0.00 | 4.03 | 5.43 | 2.05 | -0.2399 | 31.36 | -- |
| Baxter International Inc | 11.24bn | -900.00m | 10.13bn | 37.50k | -- | 1.65 | 125.07 | 0.901 | -1.75 | -1.87 | 21.89 | 11.92 | 0.4906 | 3.64 | 6.14 | 299,840.00 | -3.93 | -2.30 | -4.96 | -2.83 | 30.68 | 36.76 | -8.00 | -5.74 | 1.56 | 2.67 | 0.6083 | -- | 5.72 | -0.7461 | -167.06 | -- | -6.27 | -11.45 |
| Revvity Inc | 2.86bn | 239.88m | 10.69bn | 11.00k | 46.14 | 1.48 | 16.56 | 3.74 | 2.07 | 2.08 | 24.49 | 64.57 | 0.2326 | 3.46 | 4.15 | 259,641.00 | 1.95 | 3.23 | 2.13 | 3.58 | 54.77 | 58.48 | 8.40 | 13.58 | 1.40 | 5.01 | 0.3075 | 8.08 | 3.67 | -5.47 | -15.26 | -19.91 | -1.05 | 0.00 |
| Guardant Health Inc | 982.02m | -416.28m | 12.10bn | 2.49k | -- | -- | -- | 12.32 | -3.31 | -3.31 | 7.83 | -0.7602 | 0.5613 | 4.45 | 7.92 | 394,385.90 | -23.79 | -25.70 | -28.02 | -28.93 | 64.46 | 63.20 | -42.39 | -76.30 | 4.56 | -- | 1.07 | -- | 32.88 | 27.92 | 4.61 | -- | -2.23 | -- |
| Solventum Corp | 8.33bn | 1.56bn | 12.66bn | 20.00k | 8.23 | 2.51 | 6.19 | 1.52 | 8.87 | 8.87 | 47.48 | 29.10 | 0.5791 | 3.81 | 8.01 | 416,250.00 | 10.82 | -- | 13.58 | -- | 53.57 | 56.92 | 18.69 | 15.05 | 0.8906 | 2.05 | 0.4993 | -- | 0.8602 | 2.72 | 224.84 | 6.46 | 6.94 | -- |
| Globus Medical Inc | 2.94bn | 537.87m | 12.69bn | 6.00k | 23.84 | 2.77 | 15.55 | 4.32 | 3.93 | 3.93 | 21.44 | 33.86 | 0.5569 | 1.35 | 4.75 | 489,821.80 | 10.19 | 6.18 | 11.69 | 6.89 | 67.41 | 66.20 | 18.30 | 12.25 | 2.74 | -- | 0.0002 | 0.00 | 16.65 | 30.08 | 422.28 | 39.37 | 22.34 | -- |
| Penumbra Inc | 1.40bn | 177.69m | 13.43bn | 4.70k | 75.68 | 9.41 | 68.83 | 9.57 | 4.52 | 4.52 | 35.73 | 36.39 | 0.8356 | 1.10 | 7.85 | 298,652.10 | 10.58 | 4.03 | 11.77 | 4.49 | 67.14 | 64.57 | 12.66 | 5.39 | 4.29 | -- | 0.0159 | 0.00 | 17.50 | 20.16 | 1,168.11 | -- | 20.82 | -- |
| Align Technology Inc | 4.03bn | 410.35m | 13.47bn | 20.29k | 33.40 | 3.33 | 20.80 | 3.34 | 5.66 | 5.66 | 55.59 | 56.74 | 0.6483 | 5.33 | 3.85 | 198,864.70 | 6.59 | 8.11 | 9.67 | 11.97 | 68.27 | 70.62 | 10.17 | 12.31 | 1.24 | -- | 0.00 | 0.00 | 0.899 | 10.30 | -2.61 | -25.40 | -7.94 | -- |
Data as of Mar 03 2026. Currency figures normalised to Revvity Inc's reporting currency: US Dollar USD
67.95%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| T. Rowe Price Investment Management, Inc.as of 31 Dec 2025 | 22.45m | 19.80% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 12.16m | 10.72% |
| Edgepoint Investment Group, Inc.as of 31 Dec 2025 | 8.54m | 7.53% |
| T. Rowe Price Associates, Inc. (IM)as of 31 Dec 2025 | 8.43m | 7.44% |
| Janus Henderson Investors US LLCas of 31 Dec 2025 | 8.07m | 7.12% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 5.64m | 4.97% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 4.31m | 3.80% |
| Geode Capital Management LLCas of 31 Dec 2025 | 2.89m | 2.55% |
| Dimensional Fund Advisors LPas of 31 Dec 2025 | 2.45m | 2.16% |
| Invesco Capital Management LLCas of 31 Dec 2025 | 2.11m | 1.86% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
